Onexio Biosystems LLC: Company Profile

Background

Overview

Onexio Biosystems LLC, founded in 2016, is a biotechnology company specializing in high-throughput screening (HTS) platforms that support co-culture and multi-culture applications. The company's flagship product, the microDUO, is a microplate technology designed to enhance the relevance of assays in drug discovery and chemical toxicity testing. By facilitating intercellular interactions through micro-scale diffusion channels between adjacent wells, the microDUO integrates seamlessly into existing automated HTS workflows.

Mission and Vision

Onexio Biosystems aims to bridge the gap between traditional animal testing models and modern HTS techniques by providing innovative solutions that improve the physiological relevance of in vitro assays. The company's vision is to advance drug discovery and chemical safety testing by offering cost-effective and user-friendly platforms that enhance assay accuracy and predictive value.

Industry Significance

In the biotechnology sector, particularly within drug discovery and chemical toxicity testing, the ability to replicate human cellular interactions in vitro is crucial. Onexio's microDUO technology addresses this need by enabling co-culture and multi-culture studies, thereby improving the predictive power of HTS assays and potentially reducing reliance on animal models.

Key Strategic Focus

Core Objectives

Enhancing Assay Relevance: Developing platforms that incorporate intercellular interactions to improve the predictive accuracy of HTS assays.

Integration with Existing Workflows: Designing technologies that are compatible with standard HTS instrumentation, facilitating seamless adoption in research and development settings.

Cost-Effectiveness: Providing affordable solutions that do not compromise on assay quality or complexity.

Areas of Specialization

Co-Culture and Multi-Culture Systems: Creating in vitro models that mimic complex cellular environments to better predict human responses.

High-Throughput Screening Platforms: Developing microplate technologies that support large-scale, automated testing processes.

Key Technologies Utilized

Micro-Scale Diffusion Channels: Incorporating micro-scale channels within microplates to facilitate intercellular communication.

ANSI/SLAS Standard Formats: Ensuring compatibility with industry-standard microplate formats (96, 384, 1536 wells) for easy integration into existing HTS systems.

Primary Markets Targeted

Pharmaceutical Industry: Enhancing drug discovery processes by providing more accurate in vitro models.

Chemical Safety Testing: Improving the assessment of chemical toxicity through more relevant assay systems.

Financials and Funding

Funding History

Onexio Biosystems has raised a total of $80,000 in funding. The company participated in the MassChallenge accelerator program, which provided non-equity assistance to support its development.

Utilization of Capital

The funds have been utilized to advance the development of the microDUO platform, including design, fabrication, validation, and assay development. Additionally, the capital has supported the integration of the technology into existing HTS workflows and the expansion of the company's product offerings.

Pipeline Development

Key Pipeline Candidates

The primary focus of Onexio Biosystems is the microDUO platform, which is designed to support co-culture and multi-culture applications in HTS. The company has filed patents related to this technology, indicating ongoing development and potential future applications.

Stages of Development

Design and Fabrication: Completed the initial design and fabrication of the microDUO microplate.

Validation: Conducted validation studies to ensure the platform's functionality and compatibility with standard HTS systems.

Assay Development: Developed assays utilizing the microDUO platform to demonstrate its applicability in drug discovery and chemical toxicity testing.

Target Conditions

The microDUO platform is intended to improve the relevance of assays in drug discovery and chemical toxicity testing, particularly by facilitating intercellular interactions that are often absent in traditional mono-culture assays.

Anticipated Milestones

While specific timelines are not publicly disclosed, the company is expected to continue refining the microDUO platform and expanding its applications in the coming years.

Technological Platform and Innovation

Proprietary Technologies

MicroDUO Microplate: A patented microplate design featuring micro-scale diffusion channels between adjacent wells, enabling co-culture and multi-culture studies in HTS.

Significant Scientific Methods

Co-Culture Assays: Utilizing co-culture systems to replicate intercellular interactions and improve assay relevance.

High-Content Imaging: Employing imaging techniques to analyze assay endpoints such as fluorescence, luminescence, or absorbance.

AI-Driven Capabilities

Currently, there is no publicly available information indicating the use of AI-driven capabilities within Onexio Biosystems' technological platform.

Leadership Team

Executive Profiles

Tony Jimenez-Torres – Co-Founder and Chief Executive Officer (CEO): Dr. Jimenez-Torres holds a Ph.D. in Biomedical Engineering and has over 12 years of experience in designing microphysiological systems for in vitro disease modeling and HTS. He is the lead inventor of the microDUO technology and oversees its design, fabrication, validation, and assay development.

Brian Johnson – Co-Founder and Chief Scientific Officer (CSO): Dr. Johnson earned a Ph.D. in Molecular and Environmental Toxicology and has over 10 years of experience engineering multi-culture and microphysiological models to better mimic in vivo biology. He has been recognized for his work in incorporating drug metabolism into HTS and continues to develop innovative solutions to increase physiological relevance in vitro.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in drug discovery and chemical toxicity testing, is evolving towards more physiologically relevant in vitro models. Companies are increasingly focusing on technologies that replicate complex cellular interactions to improve the predictive accuracy of assays.

Competitor Analysis

Ayoxxa Biosystems: Develops protein chip platforms capable of detecting multiple biomarkers from small biological samples, aiming to enhance the efficiency of biomarker detection in biomedical research.

Imagen Energy: Specializes in electric vehicle charging solutions within the sustainable energy sector, focusing on power density and accessibility.

Universal Real Time Power Conversion: Offers simulation tools for power conversion systems, enabling various simulation methods to model complex systems.

Strategic Collaborations and Partnerships

Onexio Biosystems has engaged in collaborations to advance its technology, including a materials transfer agreement with the U.S. Environmental Protection Agency (EPA) to support chemical safety research.

Operational Insights

Onexio's microDUO platform offers a user-friendly assay setup that requires standard operational knowledge, distinguishing it from other technologies that may require extensive handling and unique expertise.

Strategic Opportunities and Future Directions

The company is well-positioned to expand its product range by developing innovative solutions that increase physiological relevance in vitro, including organoid multi-culture systems. This strategic direction aligns with the growing demand for more accurate in vitro models in drug discovery and chemical toxicity testing.